Clinical Relevance
First level information About Clinical Relevance & List of Abbreviations |
▶ The AC-13 pattern has formerly been considered highly specific for SLE, but this specificity is debated (69, 70) ▶ If SLE is clinically suspected, it is recommended to perform a follow-up test for anti-PCNA antibodies; the antigen is included in several routine ENA profiles (69) ▶ Recent studies with antigen-specific immunoassays show clinical associations also with SSc, AIM, RA, HCV, and other conditions (70–73) |
First level information references |
69. Miyachi K, Fritzler MJ, Tan EM. Autoantibody to a nuclear antigen in proliferating cells. J Immunol 1978;121:2228–34. 70. Vermeersch
P, De Beeck KO, Lauwerys BR, et al. Antinuclear antibodies directed
against proliferating cell nuclear antigen are not specifically
associated with systemic lupus erythematosus. Ann Rheum Dis
2009;68:1791–3. 71. Mahler
M, Burlingame RW, Wu J, et al. Serological and clinical associations of
anti-PCNA antibodies in systemic lupus erythematosus detected by a
novel chemiluminescence assay. Arthritis Rheum 2011;63. 72. Mahler
M, Miyachi K, Peebles C, et al. The clinical significance of
autoantibodies to the proliferating cell nuclear antigen (PCNA).
Autoimmun Rev 2012;11:771–5. 73. Hsu
TC, Tsay GJ, Chen TY, et al. Anti-PCNA autoantibodies preferentially
recognize C-terminal of PCNA in patients with chronic hepatitis B virus
infection. Clin Exp Immunol 2006;144:110–6. |
Second level information |
▶ A major challenge in deriving an association of the AC‐13 pattern with antibodies to the classical 35 kDa PCNA (elongation factor of DNA polymerase delta auxiliary protein) is that “PCNA” is known to be a macromolecular complex where targets other than the ‘classical’ 35 kDa PCNA are present. In addition, a number of other apparently unrelated targets can also produce an AC‐13‐like pattern by HEp‐2 IIFA (27) |
Second level information references |
27. Takeuchi
K, Kaneda K, Kawakami I, et al. Autoantibodies recognizing proteins
copurified with PCNA in patients with connective tissue diseases. Mol
Biol Rep 1996;23:243‐6. |
FAQ |
No FAQ received |